Günter Frankenne

Mr. Frankenne is an economist and has many years of outstanding experience in the pharmaceutical industry. He served as CEO of WANDER PHARMA, Germany, and as CEO of SANDOZ AG, Germany. He was involved in the 3-year merger-process between Ciba-Geigy and Sandoz to form NOVARTIS.

Furthermore, he headed committees at the Bundesverband der Pharmazeutischen Industrie (BPI) and Verband forschender Arzneimittelhersteller (VFA), where he served as Deputy Chairman of the board.
Mr. Frankenne is currently a Board member of “Forum Medizin Technik und Pharma” (initiated by the Ministry of Economic Affairs in Bavaria) and acts as consultant for Health Care companies (Bio Technologies, Pharma and MedTech). In this capacity, he holds positions in various supervisory boards.